Dual targeting of tafi and pai-1
AssigneesKatholieke Universiteit Leuven, Inserm (Institut National De La Sante Et De La Recherche Medicale), Universite de Caen Basse Normandie, Centre Hospitalier Universitaire de Caen
InventorsPaul DECLERCK, Simon DE MEYER, Nick GEUKENS, Ann GILS, Marina RUBIO, Denis VIVIEN, Tine WYSEURE
Life of this patent
Estimating the term…
Abstract
Disclosed herein is a bispecific inhibitor for use in treating thrombotic disorders, such as acute thrombotic disorders like stroke and thromboembolism. The bispecific inhibitor is based on monoclonal antibodies targeting TAFI and PAI-1, and shows efficacy in the presence or the absence of plasminogen activators such as tissue-type plasminogen activator (tPA).
Claims12
1-19. (canceled)
A method of treating or preventing an acute thrombotic disorder in a patient, comprising the step of administering a bispecific antibody against TAFI and PAI-1, wherein said antibody comprises
- a. a first targeting domain that specifically binds to Thrombin Activatable Fibrinolysis Inhibitor (TAFI) and comprises complementary determining regions (CDRs) represented by the amino acid sequences SEQ ID NO:1 of CDR1H, SEQ ID NO:2 of CDR2H, SEQ ID NO:3 of CDR3H, SEQ ID NO:4 of CDR1L, SEQ ID NO:5 of CDR2L, and SEQ ID NO:6 of CDR3L, and
- b. a second targeting domain that specifically binds to Plasminogen Activator Inhibitor-1 (PAI-1) and comprises complementary determining regions (CDRs) represented by SEQ ID NO:7 of CDR1H, SEQ ID NO:8 of CDR2H, SEQ ID NO:9 of CDR3H, SEQ ID NO:10 of CDR1L, SEQ ID NO:11 of CDR2L and SEQ ID NO:12 of CDR3L.
Dependencies are inferred from the claim text.